Literature DB >> 16061677

Halogenated thymidine analogues restore the expression of silenced genes without demethylation.

Jun Fan1, Ei-ichi Kodama, Yasuhiro Koh, Mitsuyoshi Nakao, Masao Matsuoka.   

Abstract

Transcriptional silencing of tumor suppressor genes by aberrant DNA methylation is a characteristic frequently observed in cancer cells. Therefore, reversing this process is a therapeutic target against cancer. In this study, we established a screening system for silencing inhibitors with cell lines transfected by a retroviral vector containing a luciferase gene. More than 100 nucleosides were tested for antisilencing activity with a selected clone in which the silenced expression of luciferase could be recovered by 5-aza-2'-deoxycytidine. A group of halogenated thymidine analogues was found to reactivate transcription of not only the reporter retrovirus vector but also endogenous glutathione-S-transferase 1 gene, without influence to DNA hypermethylation. Gel mobility shift assay showed that 5-bromo-2'-deoxyuridine (BrdUrd) or 5-iodo-2'-deoxyuridine incorporation did not affect the binding of the methyl-CpG binding protein motif to methylated DNA. Finally, in the retroviral promoter, BrdUrd treatment increased the acetylated histone H3 level and decreased methylation of histone H3 Lys9 in accordance with recovered transcription. This study shows that halogenated thymidines have an antisilencing effect without changing DNA methylation status by interfering with step(s) between DNA methylation and histone acetylation.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16061677     DOI: 10.1158/0008-5472.CAN-04-3495

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  4 in total

1.  HTLV-1 bZIP factor impairs cell-mediated immunity by suppressing production of Th1 cytokines.

Authors:  Kenji Sugata; Yorifumi Satou; Jun-ichirou Yasunaga; Hideki Hara; Kouichi Ohshima; Atae Utsunomiya; Masao Mitsuyama; Masao Matsuoka
Journal:  Blood       Date:  2011-11-28       Impact factor: 22.113

2.  Broad antiretroviral activity and resistance profile of the novel human immunodeficiency virus integrase inhibitor elvitegravir (JTK-303/GS-9137).

Authors:  Kazuya Shimura; Eiichi Kodama; Yasuko Sakagami; Yuji Matsuzaki; Wataru Watanabe; Kazunobu Yamataka; Yasuo Watanabe; Yoshitsugu Ohata; Satoki Doi; Motohide Sato; Mitsuki Kano; Satoru Ikeda; Masao Matsuoka
Journal:  J Virol       Date:  2007-10-31       Impact factor: 5.103

3.  Therapeutic cloning: promises and issues.

Authors:  Charlotte Kfoury
Journal:  Mcgill J Med       Date:  2007-07

4.  BCR-ABL1-induced downregulation of WASP in chronic myeloid leukemia involves epigenetic modification and contributes to malignancy.

Authors:  Welbert O Pereira; Daniel D De Carvalho; Maria Emilia Zenteno; Beatriz F Ribeiro; Jacqueline F Jacysyn; Luiz R Sardinha; Maria A Zanichelli; Nelson Hamerschlak; Gareth E Jones; Katia B Pagnano; Fabiola A Castro; Yolanda Calle; Gustavo P Amarante-Mendes
Journal:  Cell Death Dis       Date:  2017-10-12       Impact factor: 8.469

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.